• Ability to understand the study procedures and methods, participate voluntarily and be able to complete the study according to the protocol requirements, and sign the informed consent form (ICF) in writing;

• Aged 18-70 years old on the date of signing the ICF (including the threshold), both male and female;

• At the time of screening, male subjects weighing no less than 50 kg and female subjects weighing no less than 45 kg; body mass index (BMI): 18\

∙ 32 kg/m2 (including the threshold);

• Normal or abnormal physical examination, 12-ECG, vital signs, chest frontal and lateral radiographs/CT, abdominal ultrasound, and laboratory tests (blood routine, blood biochemistry, urine routine, coagulation function, etc.) in the screening and baseline periods were not clinically significant.

• The demographic means of subjects in the normal liver function group (Group C) at screening must meet the following matching criteria:

‣ BMI matched to the hepatic impairment group (Group A + Group B) with a mean value ± 15%;

⁃ Age-matched to the hepatic impairment group (Group A + Group B), mean ± 10 years;

⁃ Sex-matched to liver impairment group (Group A + Group B), mean value ± 1 case;

• Glomerular filtration rate (eGFR) ≥75 mL/min/1.73m2 calculated using the Chronic Kidney Disease Epidemiology Collaborative Study Group (CKD-EPI) formula;

• Subjects with childbearing potential must agree to have no plans for childbearing and voluntarily use highly effective contraception with their partner from the time of signing the ICF until 1 month after administration of the test drug, and to avoid sperm/egg donation. Female subjects of childbearing potential must have a negative serum pregnancy test at both screening and baseline and not be breastfeeding.

• For subjects with hepatic impairment, the following inclusion criteria must also be met:

• Not on medication within 4 weeks prior to screening, or have at least 4 weeks of stable medication for hepatic impairment and/or other co-morbidities requiring long-term treatment;

• Child-Pugh classification of Class A or B (without the use of albumin within 14 days), which is chronic liver injury caused by previous primary liver diseases, including but not limited to non-alcoholic steatohepatitis, viral hepatitis (hepatitis B, hepatitis C), etc.